Novartis (NVS) (OTCPK:NVSEF) has announced that its next-generation malaria treatment, KLU156 (GanLum), developed with Swiss ...

New England Biolabs (NEB®) today announces the release of the NEBNext Flu A Integrated Indexing Primer Module (NEB #E3436), ...

Despite strong evidence for metronidazole, amoebiasis persists as a global burden, highlighting gaps in diagnostics and ...

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

Alok Dadhich, Chief Business Officer of LifeCell Diagnostics, said "LifeCell envisions a future in which preventive healthcare is a way of life. Our mission is to make early and accurate diagnostics ...

Novartis NVS reported positive top-line data from a late-stage study of its investigational new malaria treatment candidate, ...

Simple, Accurate, Affordable Solution for Pharmacogenomics Profiling to Identify Genetic Biomarkers Associated with Drug Response-- --Learn ...

This manuscript reports on the application of ribosome profiling (EZRA-seq and eRF1-seq) combined with massively parallel reporter assays to identify and characterize a GA-rich element associated with ...

The global Wastewater Surveillance Market, valued at US$0.82 billion in 2024, stood at US$0.88 billion in 2025 and is ...

25, clinicians, research associates and members of the public gathered for a demonstration of the latest technology in lung ...

The cohesin subunit Scc1 returns and reconstitutes the complex with Smc1–Smc3 in late mitosis upon DNA double-strand breaks, although it does not participate in homologous recombination-driven MAT ...

Novartis phase III trial for next-generation malaria treatment KLU156 meets primary endpoint, with potential to combat antimalarial resistance: Basel Friday, November 14, 2025, 09 ...